TECHNICAL SPECIFICATION

ISO/TS 10993-20

First edition 2006-08-01

Biological evaluation of medical devices —

Part 20:

Principles and methods for immunotoxicology testing of medical devices

Évaluation biologique des dispositifs médicaux —

Partie 20: Principes et méthodes relatifs aux essais d'immunotoxicologie des dispositifs médicaux



PDF disclaimer

This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat accepts no liability in this area.

Adobe is a trademark of Adobe Systems Incorporated.

Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below

Anis document is a preview denotated by this

© ISO 2006

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office Case postale 56 • CH-1211 Geneva 20 Tel. + 41 22 749 01 11 Fax + 41 22 749 09 47 E-mail copyright@iso.org Web www.iso.org

Published in Switzerland

Cont	ents Pag	е
Forewo	ordi	V
Introdu	uction	/i
1	Scope	1
2	Normative references	1
3	Terms and definitions	1
4	Risk assessment and risk management	2
5	Identification of hazards	2
6 6.1 6.2 6.3	Methods of assessment of immunotoxicity	4 5
6.4 6.5 6.6	Immunosuppression Immunostimulation Hypersensitivity Auto-immunity	7 7
7	Extrapolation of data provided by pre-clinical assays	
	A (informative) Current state of knowledge	
Annex	B (informative) Clinical experience with medical devices	2
Annex	C (informative) Flow chart for immunotoxicity testing 1	4

Bibliography

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in Maison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

In other circumstances, particularly when there is an urgent market requirement for such documents, a technical committee may decide to publish other types of normative document:

- an ISO Publicly Available Specification (ISOPAS) represents an agreement between technical experts in an ISO working group and is accepted for publication if it is approved by more than 50 % of the members of the parent committee casting a vote;
- an ISO Technical Specification (ISO/TS) represents an agreement between the members of a technical committee and is accepted for publication if it is approved by 2/3 of the members of the committee casting a vote.

An ISO/PAS or ISO/TS is reviewed after three years in order to decide whether it will be confirmed for a further three years, revised to become an International Standard, or withdrawn. If the ISO/PAS or ISO/TS is confirmed, it is reviewed again after a further three years, at which time it must either be transformed into an International Standard or be withdrawn.

Attention is drawn to the possibility that some of the elements of this comment may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO/TS 10993-20 was prepared by Technical Committee ISO/TC 194, *Biological evaluation of medical devices*.

ISO/TS 10993 consists of the following parts, under the general title Biological evaluation of medical devices:

- Part 1: Evaluation and testing
- Part 2: Animal welfare requirements
- Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
- Part 4: Selection of tests for interactions with blood
- Part 5: Tests for in vitro cytotoxicity
- Part 6: Tests for local effects after implantation
- Part 7: Ethylene oxide sterilization residuals
- Part 9: Framework for identification and quantification of potential degradation products

- Part 10: Tests for irritation and delayed-type hypersensitivity
- Part 11: Tests for systemic toxicity
- Part 12: Sample preparation and reference materials
- Part 13: Identification and quantification of degradation products from polymeric medical devices
- Part 14: Identification and quantification of degradation products from ceramics
- Part 15: Identification and quantification of degradation products from metals and alloys
- Part 16: Toxicokinetic study design for degradation products and leachables
- Part 17: Establishment of allowable limits for leachable substances
- Part 18: Chemical characterization of materials
- Part 19: Physico-chemical porphological and topographical characterization of materials
- Part 20: Principles and methods for immunotoxicology testing of medical devices

 Orealies

 Ore

© ISO 2006 – All rights reserved

Introduction

International and European Standards are the main focus for demonstration of the safety and compliance of medical devices. There has been increasing attention over the past few years on the potential for medical devices to cause changes in the immune system. It was felt necessary to provide guidance on how to address adverse effects of medical devices on the immune system. As there are no standardized tests available, this document provides a framework on how to approach the evaluation of immunotoxicity.

The intention of this document is:

to summarize the current state					including	information	on
methods of assessment of imp	unotoxicity and	their p	redictiv	e value;			

to identify what the problems are and how they have been dealt with in the past.

For clinical indications of immune alterators due to medical devices, an extensive literature review has been performed, primarily through Medline. The key areas which have been researched are:

- nosuppression;
 nostimulation;
 sensitivity;
 ic inflammation;
 nmunity.
 vwords are linked with the following materials:
 cs and other polymers;
 s;
 nics, glasses and composites;
 gical materials.
 See also Table 1 for possibilities of interaction of materials with the immune system. immunosuppression; immunostimulation; hypersensitivity; chronic inflammation;
- autoimmunity.

These key words are linked with the following materials:

- plastics and other polymers;
- metals;
- ceramics, glasses and composites;
- biological materials.

NOTE

Biological evaluation of medical devices —

Part 20:

Principles and methods for immunotoxicology testing of medical devices

1 Scope

This part of ISO 10993 presents an overview of immunotoxicology with particular reference to the potential immunotoxicity of medical devices. It gives guidance on methods for testing for immunotoxicity of various types of medical devices.

This part of ISO 10993 is based on several publications written by various groups of immunotoxicologists over the last few decades in which the development of immunotoxicology as a separate entity within toxicology took place.

The current state of knowledge with regard to immunotoxicity is described in Annex A. A summary of clinical experience to date with immunotoxicology associated with medical devices is given in Annex B.

NOTE See also Bibliographic Reference [11].

2 Normative references

The following referenced documents are indispensable to the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 14971, Medical devices — Application of risk management to medical devices

ISO 10993-1, Biological evaluation of medical devices — Part 1: Evaluation and testing

ISO 10993-2, Biological evaluation of medical devices — Part 2: Animal welfare requirements

ISO 10993-6, Biological evaluation of medical devices — Part 6: Tests for local effects after implantation

ISO 10993-10, Biological evaluation of medical devices — Part 10: Tests for irritation and delayed-type hypersensitivity

ISO 10993-11:2006, Biological evaluation of medical devices — Part 11: Test for systemic toxicity

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

3.1

immunotoxicology

study of the adverse health effects that result, directly or indirectly, from the interaction of xenobiotics with the immune system